APOB and inherited lipid metabolism disorder: A study of apoB kinetics after 120 mg of torcetrapib, with or without atorvastatin, which was given to subjects with dyslipidaemia, demonstrated that torcetrapib reduced LDL apoB by increasing its fractional catabolic rate (FCR).